Tech Company Financing Transactions
SAB Biotherapeutics Funding Round
SAB Biotherapeutics, based in Sioux Falls, secured $14 million in funding from MSD Capital and South Dakota Equity Partners.
Transaction Overview
Company Name
Announced On
7/20/2020
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Series B
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2301 E 60th St. N
Sioux Falls, SC 57104
USA
Sioux Falls, SC 57104
USA
Phone
Website
Email Address
Overview
A natural match for the complexity of human disease. Modern medicine struggles to keep pace with the emergence, mutation, and diversity of disease. The body's natural defense system produces polyclonal antibodies against invaders such as viruses, allergens, bacteria, toxins, and other pathogens.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Eddie Hamilton
Chief Executive Officer
Eddie Sullivan
Chief Financial Officer
Charles Randall
Chief Marketing Officer
Melissa Ullerich
Chief Medical Officer
Thomas Luke
Chief Scientific Officer
Christoph Bausch
Vice President
Hua Wu
VP - Bus. Development
Rick Finnegan
Browse more venture capital transactions:
Prev: 7/20/2020: Teller venture capital transaction
Next: 7/20/2020: Spin Memory venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC transactions on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs